Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:alsoKnownAs |
gptkb:seliciclib
|
| gptkbp:CASNumber |
1009820-21-6
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Cyclacel_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C16H19N5O
|
| https://www.w3.org/2000/01/rdf-schema#label |
CYC202
|
| gptkbp:indication |
gptkb:cancer
gptkb:Cushing's_disease HIV infection rheumatoid arthritis |
| gptkbp:intendedUse |
anticancer agent
|
| gptkbp:mechanismOfAction |
CDK inhibitor
|
| gptkbp:molecularWeight |
297.36 g/mol
|
| gptkbp:PubChem_CID |
123631
CHEMBL1477 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
2-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine
R-roscovitine |
| gptkbp:target |
gptkb:CDK7
gptkb:CDK9 gptkb:CDK2 |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:bfsParent |
gptkb:roscovitine
|
| gptkbp:bfsLayer |
6
|